Insider Selling: Werewolf Therapeutics (NASDAQ:HOWL) Major Shareholder Sells $76,012.80 in Stock

Werewolf Therapeutics, Inc. (NASDAQ:HOWL) major shareholder Ansbert Gadicke sold 68,480 shares of Werewolf Therapeutics stock in a transaction on Friday, November 7th. The stock was sold at an average price of $1.11, for a total transaction of $76,012.80. Following the sale, the insider owned 5,836,240 shares in the company, valued at $6,478,226.40. This represents a 1.16% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Large shareholders that own at least 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

Ansbert Gadicke also recently made the following trade(s):

• On Wednesday, November 12th, Ansbert Gadicke sold 40,669 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $1.09, for a total transaction of $44,329.21.
• On Tuesday, November 11th, Ansbert Gadicke sold 55,810 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $1.14, for a total transaction of $63,623.40.
• On Monday, November 10th, Ansbert Gadicke sold 48,570 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $1.18, for a total value of $57,312.60.
• On Thursday, November 6th, Ansbert Gadicke sold 54,452 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $1.21, for a total value of $65,886.92.
• On Wednesday, November 5th, Ansbert Gadicke sold 47,950 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $1.22, for a total value of $58,499.00.
• On Tuesday, November 4th, Ansbert Gadicke sold 140,488 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $1.22, for a total value of $171,395.36.
• On Monday, November 3rd, Ansbert Gadicke sold 94,063 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $1.29, for a total value of $121,341.27.
• On Friday, October 31st, Ansbert Gadicke sold 114,044 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $1.28, for a total value of $145,976.32.
• On Thursday, October 30th, Ansbert Gadicke sold 86,936 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $1.43, for a total transaction of $124,318.48.
• On Wednesday, October 29th, Ansbert Gadicke sold 134,240 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $1.55, for a total transaction of $208,072.00.

Werewolf Therapeutics Price Performance

Shares of Werewolf Therapeutics stock opened at $0.92 on Friday. The stock has a market capitalization of $44.57 million, a price-to-earnings ratio of -0.57 and a beta of 0.72. The firm’s 50-day moving average price is $1.57 and its two-hundred day moving average price is $1.33. The company has a current ratio of 3.87, a quick ratio of 3.87 and a debt-to-equity ratio of 0.73. Werewolf Therapeutics, Inc. has a 1-year low of $0.60 and a 1-year high of $2.38.

Werewolf Therapeutics (NASDAQ:HOWL) last announced its earnings results on Tuesday, November 4th. The company reported ($0.36) EPS for the quarter, topping the consensus estimate of ($0.39) by $0.03. On average, equities analysts predict that Werewolf Therapeutics, Inc. will post -1.56 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Werewolf Therapeutics

Institutional investors have recently bought and sold shares of the company. Quadrature Capital Ltd acquired a new position in Werewolf Therapeutics during the second quarter valued at approximately $28,000. Qube Research & Technologies Ltd acquired a new stake in shares of Werewolf Therapeutics in the second quarter valued at approximately $48,000. Nuveen LLC bought a new position in shares of Werewolf Therapeutics during the 1st quarter worth approximately $71,000. AQR Capital Management LLC acquired a new position in shares of Werewolf Therapeutics during the 1st quarter worth approximately $79,000. Finally, Y Intercept Hong Kong Ltd bought a new stake in Werewolf Therapeutics in the 2nd quarter valued at $92,000. Institutional investors own 64.84% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts have weighed in on the stock. Zacks Research raised shares of Werewolf Therapeutics from a “hold” rating to a “strong-buy” rating in a research note on Thursday, October 16th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Werewolf Therapeutics in a research note on Wednesday, October 8th. Bank of America reduced their price objective on shares of Werewolf Therapeutics from $9.00 to $8.00 and set a “buy” rating on the stock in a research note on Monday, August 25th. Citigroup reissued a “market outperform” rating on shares of Werewolf Therapeutics in a report on Wednesday. Finally, JMP Securities reduced their target price on Werewolf Therapeutics from $4.00 to $3.00 and set a “market outperform” rating on the stock in a report on Thursday, August 21st. One analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $8.00.

About Werewolf Therapeutics

Werewolf Therapeutics, Inc, a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies.